Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2021-04-27
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04861259
- Locations
- 🇫🇷
Hôpital Robert Debré; Nephrologie pediatrique, Paris, France
🇫🇷Gh Necker Enfants Malades; Nephrologie, Paris, France
🇫🇷Hopital Tenon; Service SINRA, Paris, France
A Study to Evaluate Safety, Pharmacokinetics and Anti-Tumor Activity of RO7300490, as Single Agent or in Combination With Atezolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04857138
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇬🇧Western General Hospital; Edinburgh Cancer Center, Edinburgh, United Kingdom
A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04832854
- Locations
- 🇨🇭
Kantonsspital Winterthur; Medizinische Onkologie, Winterthur, Switzerland
🇨🇭UniversitätsSpital Zürich; Zentrum für Hämatologie und Onkologie, Klinik für Onkologie, Zürich, Switzerland
🇦🇺Cabrini Hospital Malvern, Malvern, Victoria, Australia
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
- Conditions
- Interventions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 80
- Registration Number
- NCT04826003
- Locations
- 🇳🇱
NKI/AvL, Amsterdam, Netherlands
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 510
- Registration Number
- NCT04802759
- Locations
- 🇺🇸
Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States
🇺🇸Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 50
- Registration Number
- NCT04790903
- Locations
- 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
🇫🇷CHU Montpellier - Saint ELOI, Montpellier, France
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Effect of RO7049665 on the Time to Relapse Following Steroid Tapering in Participants With Autoimmune Hepatitis (AIH)
- Conditions
- Interventions
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 2
- Registration Number
- NCT04790916
- Locations
- 🇦🇺
The Alfred Hospital - Professor Stuart Roberts' Clinic - The Alfred Centre Location, Melbourne, Victoria, Australia
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇩🇪Martin Zeitz Centrum für Seltene Erkrankungen ZSE Hamburg, Hamburg, Germany
A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
- Conditions
- Interventions
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 210
- Registration Number
- NCT04785820
- Locations
- 🇵🇱
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny, Brzozów, Poland
🇷🇺First Moscow State Medical University n.a. I.M. Sechenov, Moscow, Moskovskaja Oblast, Russian Federation
🇨🇳National Taiwan University Hospital; Oncology, Zhongzheng Dist., Taiwan
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 586
- Registration Number
- NCT04777331
- Locations
- 🇵🇱
Nmedis sp. z o.o., Rzeszów, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Barrow Neurological Institute, Phoenix, Arizona, United States
A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-03-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1036
- Registration Number
- NCT04777201
- Locations
- 🇺🇸
Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸Associated Retina Consultants, Phoenix, Arizona, United States